Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression
Oncology Times - OncTimes Talk
English - March 04, 2024 21:04 - 16 minutes - 14.3 KB - ★★★★ - 2 ratingsScience Health & Fitness Medicine oncology cancer medicine health news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Previous Episode: Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias
The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth factor receptor.
First author Xiuning Le, MD, PhD, Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center, has been discussing her group’s findings with Peter Goodwin, an OncTimesTalk correspondent.